What Do the Mid-Terms Mean for Marijuana Legalization in America?

Voters in three of four states with marijuana ballot proposals passed initiatives that loosen restrictions on the substance, but that won't necessarily result in nation-wide expansion of this policy.
Author:
Publish date:
GettyImages-810213460

The mid-term elections have further loosened marijuana restrictions in the United States. Voters in three of four states with ballot proposals on marijuana approved those initiatives.

In Utah and Missouri, voters on Tuesday decided that patients should have access to medical marijuana.

Michigan, which already had medical marijuana, became the first Midwestern state to fully legalize pot. It joins nine other states, Washington, D.C., Canada, and Uruguay in launching a regulated recreational marijuana market.

North Dakotans decisively rejected a proposal to make marijuana legal for recreational purposes.

Before Tuesday's vote, 22 American states had adopted comprehensive medical marijuana programs. California was the first, recognizing in 1996 the therapeutic uses of marijuana in easing the symptoms of serious illnesses like HIV, cancer, epilepsy, post-traumatic stress disorder, and glaucoma. Recently, marijuana's potential value for treating chronic pain has garnered attention as an alternative to opioids.

No Tipping Point

Nationally, support for marijuana has never been stronger. Seventy-two percent of Democrats and a narrow majority of Republicans—51 percent—support legalization, according to Gallup.

Strong public support and successive waves of state-level legalization in election years have led many policy analysts to argue that marijuana has reached a tipping point in the U.S.

Two-thirds of all states have now legalized some kind of marijuana. After that, the argument goes, its nationwide expansion is inevitable.

As marijuana policy researchers, we question that narrative.

Our research indicates that medical marijuana progress may well stall after this latest round of successful ballot initiatives. Recreational marijuana may continue to expand into states with legal medical marijuana but will ultimately hit a wall too.

Our caution has to do with the particular way marijuana legalization has occurred in the U.S.: at the ballot box.

Ballot Initiatives Have Power

So far, all but one of the recreational marijuana laws passed has occurred via ballot initiative, not through the state legislative process. Seven of the first eight medical marijuana laws—those in California, Alaska, Oregon, Washington, Maine, and Nevada—were also adopted via ballot initiative.

Such direct initiatives—where citizens can put a policy on the ballot for approval—are a powerful, if non-traditional, form of policymaking in the U.S.

Rather than relying on lawmakers to write and pass legislation on certain issues—often, controversial ones—ballot initiatives harness public opinion. They have been used to legalize or restrict same-sex marriage, place limitations on taxing and spending, raise the minimum wage, and much more. Some are funded by wealthy individuals with specific business interests.

Even in states where ballot initiatives have little hope of passing, they can be an important force for policy change.

In Ohio, marijuana advocates in 2015 spent over $20 million in an effort to legalize both medical and recreational marijuana in the same ballot initiative. Ohio voters overwhelmingly said no—but the campaign revealed broad support for a medical marijuana policy.

The Marijuana Policy Project, an advocacy organization, said it would put medical marijuana on Ohio's ballot in 2016. In response, Ohio's legislature moved quickly to craft and pass its own medical marijuana legislation.

In Utah, where Governor Gary Herbert opposed the expansive medical marijuana proposal passed on Tuesday, lawmakers have already promised to supercede the initiative and pass marijuana legislation that would be more acceptable to conservative state legislators and the influential Mormon Church.

The Limits of Direct Initiative

So the ballot initiative is powerful. But our analysis suggests its potential for liberalizing marijuana access in the U.S. is nearly tapped out.

Of the 17 U.S. states that still have no form of legal marijuana, only five—Idaho, Wyoming, South Dakota, Nebraska, and Missouri—allow direct initiatives.

The rest are mostly conservative places like South Carolina and Alabama, where legislatures have indicated reluctance to loosen restrictions. If voters there wanted medical or recreational marijuana, they would not have the option of bypassing policymakers to get the issue on the ballot.

Marijuana legalization won't end with the 2018 mid-terms. There is still room for recreational marijuana to expand into the 22—soon to be 24—states that have legal medicinal marijuana.

History shows that, once people grow comfortable with medical marijuana—seeing its impacts on patients and tax revenues—full legalization often follows.

In our analysis, the remaining 13 states are very unlikely to liberalize access to marijuana without a significant push by the federal government.

That's unlikely, but not impossible, under the Trump administration.

Federal law still considers marijuana an illegal Schedule I drug under the Controlled Substances Act, meaning that, as far as the U.S. government is concerned, the plant has no medical value.

The Obama administration took a hands-off approach to states' legalization, allowing them to experiment. But Trump's first attorney general, Jeff Sessions, directed Department of Justice attorneys to fully enforce federal law in legal marijuana states.

Quietly, however, the Trump administration has sought public comments on reclassifying marijuana. And the president himself has at times signaled support for leaving marijuana up to the states.

With Sessions now officially out of the Trump administration, the Department of Justice's position on marijuana enforcement could change.

And Democrats, who won control of the House of Representatives on Tuesday, have previously indicated that they could push to remove marijuana as a Schedule I drug as soon as next year.

This article was originally published on The Conversation. Read the original article. Daniel Mallinson is an assistant professor of public policy at Penn State University. Lee Hannah is an assistant professor of political science at Wright State University.

Related